Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 37-57

  Henry, David A ^a   McGettigan, Patricia ^a,b   Tonkin, Anne ^c   Hennessy, Sean ^d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b NEWCASTLE MATER HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clinical pharmacology principles; Drug action mechanism; Drug nature and potency; Drug drug interactions and pharmacokinetic mechanisms; Human response to drug genetic determinants; Inter and intra individual variability responses; Pharmacodynamic and adaptive responses; Pharmacodynamic response and age effect; Pharmacodynamics and pharmacokinetics

Indexed keywords

EID: 84889291178     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch4     Document Type: Chapter

References (71)

1. Royal Australasian College of Physicians. Available from: http://www.racp.edu.au/.
2. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872-81.
3. American Academy of Pediatrics Committee on Fetus and Newborn Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics 1983; 72: 356.
4. Nayler WG. Calcium Antagonists. London: Academic Press, 1988.
5. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology, 5th edn. Edinburgh: Churchill Livingstone, 2003.
6. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds, The Pharmacological Basis of Therapeutics, 8th edn. New York: Pergamon Press, 1990; p. 497.
7. Henry D, Lim LL-Y, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M. et al. Variability in risk of major upper gastrointestinal complications with individual NSAIDs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6.
8. Shenfield G, Le Couter DG, Rivory LP. Updates in medicine: clinical pharmacology. Med J Aust 2002; 176: 9.
9. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250: 186-200.
10. Gandhi PJ, Cambria-Kiely JA. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2003; 14: 51-8.
11. Lu Y, Mahaut-Smith MP, Huang CL-H, Vandenberg JI. Mutant MiRP1 subunits modulate HERG K+ channel gating: a mechanism for pro-arrhythmia in long QT syndrome type 6. J Physiol 2003; 551: 253-62.
12. Kendall MJ, Beeley L. Beta-adrenoceptor blocking drugs: adverse reactions and drug interactions. Pharmacol Ther 1983; 21: 351-69.
13. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal antiinflammatory agents. Am J Med 1984; 77: 19-24.
14. Graham DY, Smith JL, Spjut HJ, Torres E. Gastric adaptation. Gastroenterology 1988; 95: 327-33.
15. Garcia-Rodriguez LA, Walker LAM, Perez-Gutthann S. Nonsteroidal anti-inflammatory drugs and gastrointestinal hospitalisations in Saskatchewan: a cohort study. Epidemiology 1992; 3: 337-42.
16. Langman MJS, Weil J, Wainright P. Risk of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8.
17. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG. Association of gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure: a cohort study. BMJ 1997; 315: 1333-7.
18. Vestal RE, Wood AJ, Shand DG. Reduced beta adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther 1979; 26: 181-6.
19. Abernethy DR, Schwartz JB, Todd EL. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. Ann Intern Med 1986; 105: 329-36.
20. Podoisky DK, Isselbacher KJ. Derangements of hepatic metabolism. In: Wilson JD, Braunwald E, Isselbacher KJ, eds, Harrison's Principles of Internal Medicine, 12th edn. New York: McGraw Hill, 1991; pp. 1311-7.
21. Anon. Morphine. In: Dollery C, ed., Therapeutic Drugs, vol. 2. Edinburgh: Churchill Livingstone, 1991; pp. M225-33.
22. Grimm G, Ferenci P, Katzenschlager R, Madl C, Schneeweiss B, Laggner AN, Lenz K, Gangl A. Improvement of hepatic encephalopathy treated with flumazenil. Lancet 1988; ii: 1392-4.
23. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310: 563-72.
24. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 338: 1397-404.
25. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs. New Engl J Med 1998; 339: 713-8.
26. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X et al. For the International Primary Pulmonary Hypertension Group. Appetite-supressant drugs and the risk of primary pulmonary hypertension. New Engl J Med 1996; 335: 609-16.
27. Anon. Adalat tablets. Approved product information. In: Thomas J, ed., Prescription Products Guide. Hawthorne, Victoria: Australian Pharmaceutical Publishing, 1992, pp. 237-8.
28. Larregue M, Bressieux JM, Laidet B, Titi A. Caustic diaper dermatitis and toxic encephalopathy following the application of talc contaminated by hexachlorophene. Ann Pediatr (Paris) 1986; 33: 587-92.
29. Martin-Bouyer G, Khanh NB, Linh PD, Hoa DQ, Tuan LC, Tourneau J, et al. Epidemic of haemorrhagic disease in Vietnamese infants caused by warfarin-contaminated talcs. Lancet 1983; i: 230-2.
30. Law CM, Preece MA, Warner JO. Nocturnal adrenal suppression in children inhaling beclamethasone dipropionate (letter). Lancet 1987; i: 1321.
31. Anon. Timoptol. Approved product information. In: Thomas J, ed., Prescription Products Guide. Hawthorne, Victoria: Australian Pharmaceutical Publishing Company, 1992; p. 17401.
32. Birkett D. Drug protein binding. Aust Prescr 1992; 15: 56-7.
33. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 2003; 33 (suppl 2): 6-9.
34. Asra S, Reinhold K, Michael EW, Ulrich B. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348: 1442-8.
35. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
36. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR. The effect of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 1975; 55: 347-59.
37. Ghabrial H, Desmond PV, Watson KJ, Gijsbers AJ, Harman PJ, Breen KJ, Mashford ML. The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 1986; 30: 93-7.
38. Graham-Smith DG, Aronson JK. Pharmacokinetics. In: Oxford Textbook of Clinical Pharmacology and Drug Therapy, 2nd edn. Oxford: Oxford University Press, 1992, pp. 94-103.
39. Huang Y-S, Chern H-D, Su W-J, Wu J-C, Chang S-C, Chiang C-H et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-30.
40. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584.
41. Meyer UA. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269-96.
42. Wiholm BE, Alvan G, Bertilsson L, Sawe J, Sjoqvist F. Hydroxylation of debrisoquine in patients with lactic acidosis after phenformin. Lancet 1981; i: 1098-9.
43. Ranek L, Dalhoff K, Poulsen HE, Brosen K, Flachs H, Loft S et al. Drug metabolism and genetic polymorphism in subjects with previous halothane hepatitis. Scand J Gastroenterol 1993; 28: 677-80.
44. Jusko WJ, Eaten ML. Factors affecting theophylline disposition. In: McLeod SM, Isles A, eds, Theophylline Therapy Update. Mississauga, Ontario: Astra Pharmaceuticals Canada, 1982; pp. 19-29.
45. Anon. Carbamazepine. In: Dollery C, ed., Therapeutic Drugs, vol. 1. Edinburgh: Churchill Livingstone, 1991; pp. 49-53.
46. Anon. Propranolol. In: Dollery C, ed., Therapeutic Drugs, vol. 1. Edinburgh: Churchill Livingstone, 1991; pp. 272-8.
47. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. BMJ 1986; 292: 1548-9.
48. Bray GP, Harrison PM, O'Grady JG, Tredger JM, Williams R. Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol 1992; 11: 265-70.
49. Stockley IH. Drug Interactions, 2nd edn. Oxford: Blackwell Scientific, 1991.
50. Anon. Gastrointestinal drugs. In: McEvoy GK, ed., AHFS Drug Information. Bethesda: American Society of Hospital Pharmacists, 1990; pp. 1666-70.
51. Gugler R, Jensen JC. Omeprazole inhibits elimination of diazepam (letter). Lancet 1984; i: 969.
52. Prichard PJ, Walt RP, Kitchingman GK, Somerville KW, Langman MJ, Williams J, Richens A. Oral phenytoin kinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 534-5.
53. Henry D, Brent P, Whyte I, Mihaly G, Devenish-Meares S. Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 1987; 33: 369-73.
54. Anon. Ventricular arrthythmias due to terfenadine and astemizole. Current problems. Comm Saf Med 1992; 35: 1-2.
55. Kumana CR, Tong MKL, Li C-S, Lauder IJ, Lee JSK, Kou M et al. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin. Br J Clin Pharmacol 2003; 56: 670-8.
56. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet 1994; 26: 91.
57. Britten N, Ukoumunne O. The influence of patients' hopes of receiving a prescription on doctors' perceptions and the decision to prescribe: a questionnaire survey. BMJ 1997; 315: 1506-10.
58. Cockburn J, Pit S. Prescribing behaviour in clinical practice: patients' expectations and doctors' perceptions of patients' expectations-a questionnaire study. BMJ 1997; 315: 520-3.
59. Nikolajevic-Sarunac J, Henry DA, O'Connell DL, Robertson J. Effects of information framing on general practitioners' intentions to prescribe long term hormone replacement therapy: results of a randomized controlled trial. J Gen Intern Med 1999; 14: 591-8.
60. Freidman PD, Brett AS, Mayo-Smith MF. Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med 1996; 124: 414-21.
61. McGettigan P, Sly K, O'Connell D, Hill S, Henry D. The effects of information framing on the practices of physicians. J Gen Intern Med 1999; 14: 633-42.
62. Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J et al. Coverage by the news media of the benefits and risks of medications. N Engl J Med 2000; 342: 1645-50.
63. Moxey A, O'Connell D, McGettigan P, Henry D. Describing treatment effects to patients: how they are expressed makes a difference. J Gen Intern Med 2003; 18: 948-59.
64. Greenhalgh T, Kostopoulou O, Harries C. Making decisions about benefits and harms of medicines. BMJ 2004; 329: 47-50.
65. Bloor K, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors. BMJ 1996; 312: 1525-7.
66. Doran E, Robertson J, Rolfe I, Henry D. Patient co-payments and use of prescription medicines. Aust N Z J Public Health 2004; 28: 62-7.
67. Abel-Smith B, Grandjeat P. Pharmaceutical Consumption. Social Policy Series 38. Brussels: Commission of the European Communities, 1978.
68. Rittenhouse BE. Economic incentives and disincentives for efficient prescribing. Pharmacoeconomics 1994; 6: 222-32.
69. Seo T. Prescribing and dispensing of pharmaceuticals in Japan. Pharmacoeconomics 1994; 6: 95-102.
70. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002; 29: 1015-22.
71. Barrett-Connor E. Post-menopausal estrogen and prevention bias. Ann Intern Med 1991; 115: 455-6.